| Srorage: | Keep Cool Dry Area |
|---|---|
| Shelf Life: | 3 Years |
| Package: | Custom |
| Form: | Liquid |
| Transport Package: | Carton |
| Specification: | Diclofenac sodium |
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier | Product name | Diclofenetong enteric coated tablet |
| Main Ingredients | Diclofenac sodium |
| Adaptation disease | (1) Relieve the swelling and pain symptoms of rheumatoid arthritis, osteoarthritis, spondyloarthritis, gout arthritis, rheumatoid arthritis and other arthritis; (2) the treatment of non-articular soft tissue rheumatic pain, such as shoulder pain, tenosynovitis, bursitis, myalgia and post-exercise injury pain; (3) acute mild and moderate pain such as: post-surgery, post-trauma, post-strain, dysmenorrhea, toothache, headache, etc.; (4) it has antipyretic effect on adults and children. |
| Dosage form | Troche |
| Character | This product is a clear almost colorless liquid |
| Specification | 25mg |
| Usage and dosage | Oral. (1) As a routine dose, the initial daily dose is 100mg-150mg (4-6 tablets). For mild patients or those requiring long-term treatment, the daily dose is 75-100mg (3-4 tablets). Usually take the daily dose in 2-3 doses. (2) For primary dysmenorrhea, the usual daily dose is 50-150mg (2-6 tablets), taken in batches. The initial dose should be 50-150mg (2-6 tablets) and, if necessary, increased to a maximum dose of 200mg/ day (8 tablets/day) over several menstrual cycles. Treatment should be started as soon as symptoms appear and continued for several days, depending on the symptoms. (3)The normal dosage of children: 0.5 ~ 2.0mg/kg a day, the maximum daily dose is 3.0mg/kg, divided into 3 times. |
| Storage | Shading seal |
| Origin | China |
| Validity | 24 months |
| Tatoo | (1) patients known to be allergic to this product. (2) patients who develop asthma, urticaria or allergic reactions after taking aspirin or other nsaids. (3) Contraindicated in the treatment of perioperative pain during coronary artery bypass surgery (CABG). (4) Patients with a history of gastrointestinal bleeding or perforation after using NSAIDS. (5) Patients with active gastrointestinal ulcer/bleeding or a history of recurrent ulcer/bleeding. (6) Severe heart failure patients. |
| Notice | [Adverse reactions] 1, there are common gastrointestinal reactions, such as stomach discomfort, burning sensation, acid reflux, poor appetite, nausea, etc., stop medicine or symptomatic treatment can disappear. Long-term application may lead to gastric ulcer, gastric bleeding and gastric perforation. 2, a few edema, oliguria, electrolyte disorders. Swelling and pain at the injection site. 3, occasionally nervous system reaction (incidence (1%), such as headache, dizziness, drowsiness, excitement, etc. 4. Other rare cases include transient elevation of serum transaminase, jaundice, rash, arrhythmia, granulopenia, thrombocytopenia, etc., which can be recovered after drug withdrawal. |
| Matters needing attention (1) Use with caution if there is a history of liver and kidney damage or ulceration, especially in the elderly. The liver and kidney function should be checked during routine follow-up. (2) Due to the sodium content of this product, patients with limited sodium intake should be used with caution. (3) Avoid combination with other NSaids, including selective COX-2 inhibitors. (4) According to the need to control symptoms, the use of the lowest effective dose in the shortest treatment time can minimize the adverse reactions. (5) Gastrointestinal bleeding, ulcers, and perforation may occur at any time during treatment with all NSaids, and the risk may be fatal. These adverse events may or may not be accompanied by warning symptoms, regardless of whether the patient has a history of gastrointestinal adverse events or a history of serious gastrointestinal events. Patients with a prior history of gastrointestinal tract disease (ulcerative colitis, Crohn's disease) should use NSaids with caution to avoid exacerbating the disease. Patients should stop taking the drug when they develop gastrointestinal bleeding or ulcers. Older patients with NSaids experience an increased frequency of adverse reactions, particularly gastrointestinal bleeding and perforation, which can be fatal. (6) Clinical trials of multiple COX-2 selective and non-selective NSAIDS lasting up to 3 years have shown that the product may cause an increased risk of serious cardiovascular thrombotic adverse events, myocardial infarction and stroke, which may be fatal. All NSaids, including COX-2 selective and non-selective drugs, may have similar risks. Patients with CVD or CVD risk factors are at greater risk. Even if there are no previous cardiovascular symptoms, physicians and patients should be vigilant about the occurrence of these events. Patients should be informed of symptoms and/or signs of serious cardiovascular safety and steps to take if they occur. Patients should be alert for signs and symptoms such as chest pain, shortness of breath, weakness, slurred speech, and seek medical help immediately if any of these symptoms or signs occur. (7) Like all non-steroidal anti-inflammatory drugs (NSaids), this product can cause new onset of hypertension or worsen existing hypertension, either of which can lead to an increased rate of cardiovascular events. Non-steroidal anti-inflammatory drugs (NSaids) may affect the efficacy of these drugs in patients taking thiazide or ansa diuretics. Non-steroidal anti-inflammatory drugs (NSAIDS), including this product, should be used with caution in patients with hypertension. Blood pressure should be closely monitored at the beginning and throughout treatment. (8) Use with caution in patients with a history of hypertension and/or heart failure, such as fluid retention and edema. (9) NSAIDS, including this product, may cause fatal and serious skin adverse reactions, such as exudative dermatitis, Stevens Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN). These serious events can occur without warning. Patients should be informed of the signs and symptoms of severe skin reactions and should be discontinued at the first appearance of a skin rash or other signs of an allergic reaction. |
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}